These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25556929)

  • 1. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
    Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
    APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
    Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
    Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
    Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
    J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
    van Zandwijk N; Mathy A; Boerrigter L; Ruijter H; Tielen I; de Jong D; Baas P; Burgers S; Nederlof P
    Ann Oncol; 2007 Jan; 18(1):99-103. PubMed ID: 17060486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
    Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
    Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
    Kozlov V; Karpov I; Kovalenko S; Shamanin V
    Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
    Pinter F; Papay J; Almasi A; Sapi Z; Szabo E; Kanya M; Tamasi A; Jori B; Varkondi E; Moldvay J; Szondy K; Keri G; Dominici M; Conte P; Eckhardt S; Kopper L; Schwab R; Petak I
    J Mol Diagn; 2008 Mar; 10(2):160-8. PubMed ID: 18258923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
    Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
    Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.
    Lozano MD; Zulueta JJ; Echeveste JI; Gúrpide A; Seijo LM; Martín-Algarra S; Del Barrio A; Pio R; Idoate MA; Labiano T; Perez-Gracia JL
    Oncologist; 2011; 16(6):877-85. PubMed ID: 21572125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
    Pan JB; Hou YH; Zhang GJ
    Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
    Zhang Y; Wang Q; Han ZG; Shan L
    Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
    Janjigian YY; Park BJ; Zakowski MF; Ladanyi M; Pao W; D'Angelo SP; Kris MG; Shen R; Zheng J; Azzoli CG
    J Thorac Oncol; 2011 Mar; 6(3):569-75. PubMed ID: 21150674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.